Qualification of an IFN-γ ELISpot Assay for Monitoring Antigen-Specific T-Cell Responses in Clinical Trials of T-cell-inducing Vaccines

Abstract The IFN-γ ELISpot assay is a sensitive, widely used platform for quantifying antigen-specific T-cell responses and serves as a benchmark assay for immunomonitoring in vaccine trials. Despite its broad adoption, clinical use requires formal qualification to ensure reproducibility, reliability, and fitness for use. However, standardised, qualified ELISpot assays remain scarce for clinical trials in Africa. We present an IFN-γ ELISpot assay for measuring antigen-specific T-cell responses in human PBMCs qualified under Good Clinical Laboratory Practice (GCLP) standards. Assay performance was evaluated using predefined parameters, including linearity, precision, specificity, detection capacity, robustness, and reportable range, across multiple PBMC stimulation conditions. Linearity was assessed across six different cell inputs per well using the CEFSX stimulation. Precision was assessed via the predefined coefficient of variation (CV) threshold of ≤ 35% across the evaluated stimulation conditions. Robustness was assessed using a one-factor-at-a-time approach across different post-thawing and incubation times for the three stimulations. Strong linearity was observed across the donor samples (R2=0.90-0.98). All samples met the precision acceptance criteria across all tested conditions, demonstrating performance consistent with accepted standards in the field. Intermediate precision was similarly robust, with minimal operator-dependent variability and 94.4% of replicate values falling within the predefined acceptance limits. There was no significant effect of different post-thawing and incubation times on the assay output (p-value >0.05), and the assay achieved 100% specificity. Overall, the qualified assay demonstrated strong analytical performance and readiness for immunomonitoring in clinical vaccine trials. Importantly, this work establishes our lab as a GCLP-certified African site for clinical vaccine trial immunomonitoring of IFN-γ ELISpot assays.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-16
DOI
https://doi.org/10.21203/rs.3.rs-11483713/v1
Primary Topic
Advanced Biosensing Techniques and Applications
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Qualification of an IFN-γ ELISpot Assay for Monitoring Antigen-Specific T-Cell Responses in Clinical Trials of T-cell-inducing Vaccines

Alabi Waheed Banjoko, Zaza M. Ndhlovu, Namani Ngema, Lorraine Tshegofatso Maebele et al.
1 links
Research Square
Advanced Biosensing Techniques and Applications
preprint

Qualification of an IFN-γ ELISpot Assay for Monitoring Antigen-Specific T-Cell Responses in Clinical Trials of T-cell-inducing Vaccines

Alabi Waheed Banjoko, Zaza M. Ndhlovu, Namani Ngema, Lorraine Tshegofatso Maebele, Crystal A. Mendoza, Mali Mlaba, Tiza Ng’uni, Nitalia Naidoo
preprint en

Abstract

Abstract The IFN-γ ELISpot assay is a sensitive, widely used platform for quantifying antigen-specific T-cell responses and serves as a benchmark assay for immunomonitoring in vaccine trials. Despite its broad adoption, clinical use requires formal qualification to ensure reproducibility, reliability, and fitness for use. However, standardised, qualified ELISpot assays remain scarce for clinical trials in Africa. We present an IFN-γ ELISpot assay for measuring antigen-specific T-cell responses in human PBMCs qualified under Good Clinical Laboratory Practice (GCLP) standards. Assay performance was evaluated using predefined parameters, including linearity, precision, specificity, detection capacity, robustness, and reportable range, across multiple PBMC stimulation conditions. Linearity was assessed across six different cell inputs per well using the CEFSX stimulation. Precision was assessed via the predefined coefficient of variation (CV) threshold of ≤ 35% across the evaluated stimulation conditions. Robustness was assessed using a one-factor-at-a-time approach across different post-thawing and incubation times for the three stimulations. Strong linearity was observed across the donor samples (R2=0.90-0.98). All samples met the precision acceptance criteria across all tested conditions, demonstrating performance consistent with accepted standards in the field. Intermediate precision was similarly robust, with minimal operator-dependent variability and 94.4% of replicate values falling within the predefined acceptance limits. There was no significant effect of different post-thawing and incubation times on the assay output (p-value >0.05), and the assay achieved 100% specificity. Overall, the qualified assay demonstrated strong analytical performance and readiness for immunomonitoring in clinical vaccine trials. Importantly, this work establishes our lab as a GCLP-certified African site for clinical vaccine trial immunomonitoring of IFN-γ ELISpot assays.

Research Square
Ragon Institute of MGH, MIT and Harvard (US), Africa Health Research Institute (ZA)
Bill and Melinda Gates Foundation
Good health and well-being
Advanced Biosensing Techniques and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon